Cargando…
Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
The diagnostic work-up for non-small cell lung cancer (NSCLC) requires biomarker testing to guide therapy choices. This article is the second of a two-part series. In Part 1, we summarised evidence-based recommendations for obtaining and processing small specimen samples (i.e. pre-analytical steps)...
Autores principales: | Penault-Llorca, Frédérique, Kerr, Keith M., Garrido, Pilar, Thunnissen, Erik, Dequeker, Elisabeth, Normanno, Nicola, Patton, Simon J., Fairley, Jenni, Kapp, Joshua, de Ridder, Daniëlle, Ryška, Aleš, Moch, Holger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297263/ https://www.ncbi.nlm.nih.gov/pubmed/35857103 http://dx.doi.org/10.1007/s00428-022-03344-1 |
Ejemplares similares
-
Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022) -
IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing
por: Deans, Zandra C., et al.
Publicado: (2019) -
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
por: Thunnissen, Erik, et al.
Publicado: (2012) -
Testing for ROS1 in non-small cell lung cancer: a review with recommendations
por: Bubendorf, Lukas, et al.
Publicado: (2016) -
Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL
por: Deans, Zandra C, et al.
Publicado: (2016)